SUPRIYA.NS
SUPRIYA.NS
INE07RO01027
SUPRIYA LIFESCIENCE LTD
Loading chart...

Company Profile

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it develops drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

Related stocks

ONESOURCE.NS
ONESOURCE.NS • India
ONESOURCE SPECL PHARMA L
1,461.3 INR
1.73B USD 1Y -22.7%
CONCORDBIO.NS
CONCORDBIO.NS • India
CONCORD BIOTECH LIMITED
1,361.4 INR
1.47B USD 1Y -14.4%
4743.TWO
4743.TWO • Taiwan
ONENESS BIOTECH CO LTD
48.1 TWD
722.78M USD 1Y -26%
005690.KS
005690.KS • South Korea
Pharmicell
12,860 KRW
575.85M USD 1Y +4.7%
476830.KQ
476830.KQ • South Korea
Rznomics
26,300 KRW
550.63M USD
2617.HK
2617.HK • China
TRANSTHERA-B
10.43 HKD
541.23M USD 1Y -92.1%
085660.KQ
085660.KQ • South Korea
CHA Biotech
8,200 KRW
568.93M USD 1Y -27.7%
456160.KQ
456160.KQ • South Korea
G2GBIO
42,000 KRW
518.58M USD 1Y -37.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
48.3% p.a.
Max Drawdown (5Y)
-69.2%
Sharpe Ratio (5Y)
0.31
Beta Factor
0.63
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (48.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -69.2% in the extended horizon.
ende